Title |
Novel ALK inhibitors in clinical use and development
|
---|---|
Published in |
Journal of Hematology & Oncology, February 2015
|
DOI | 10.1186/s13045-015-0122-8 |
Pubmed ID | |
Authors |
Chaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, Muhammad Furqan, Varun Mittal, Shundong Cang, Delong Liu |
Abstract |
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 1% |
Unknown | 75 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 16% |
Other | 11 | 14% |
Researcher | 10 | 13% |
Student > Ph. D. Student | 8 | 11% |
Student > Bachelor | 7 | 9% |
Other | 15 | 20% |
Unknown | 13 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 24% |
Biochemistry, Genetics and Molecular Biology | 17 | 22% |
Agricultural and Biological Sciences | 14 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Chemistry | 4 | 5% |
Other | 4 | 5% |
Unknown | 15 | 20% |